The Beauty Health Company, known for its flagship brand Hydrafacial, has announced that its microneedling device, SkinStylus™, has received new clearance from the U.S. Food and Drug Administration (FDA) for use on facial acne scarring in patients aged 22 years and older with Fitzpatrick skin types I, II, and III. This makes it the only microneedling device that is FDA-cleared for both facial and abdominal use.
The FDA clearance is a significant achievement for SkinStylus™, particularly as it comes just five months after BeautyHealth acquired the brand. This milestone reflects BeautyHealth’s commitment to innovation and brand building, positioning SkinStylus™ for rapid growth within the company’s multi-brand ecosystem.
Microneedling is a popular and minimally invasive treatment, expected to reach a $1 billion market size in the U.S. by 2030. The procedure involves using small needles to create controlled micro injuries, stimulating collagen and elastin production for smoother and firmer skin.
SkinStylus™, classified as a Class II Medical Device by the FDA, offers a unique feature set designed to meet the needs of medical and aesthetic professionals. Previously cleared for improving the appearance of surgical or traumatic hypertrophic scars on the abdomen, the new clearance expands its usage to address facial acne scarring.
BeautyHealth’s vision is to become a leading platform in beauty, health, and wellness, leveraging its portfolio of exceptional brands to achieve category leadership. SkinStylus™ is available at providers across the United States, and more information can be found on SkinStylus.com.